Evidence Snapshot

ATP-dependent translocase ABCB1

CHEMBL4302 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:20Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL4302

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats ATP-dependent translocase ABCB1 as ChEMBL target CHEMBL4302, mapped to UniProt P08183. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

ATP-dependent translocase ABCB1

SINGLE PROTEIN · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL4302

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

P08183

ATP-dependent translocase ABCB1

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why ATP-dependent translocase ABCB1 matters

As of 2026-09-14

ATP-dependent translocase ABCB1 is reviewed as ATP-dependent translocase ABCB1 (UniProt P08183); ATP-dependent translocase ABCB1 shows late clinical disease relevance led by leukemia. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 109 approved drugs, 6413 compounds, and 2968 assays, with lead potency reaching pChEMBL 11.0.

Protein context

ATP-dependent translocase ABCB1

ATP-dependent translocase ABCB1 Sequence length is 1280 aa.

Review this target as ATP-dependent translocase ABCB1, mapped to UniProt P08183. Sequence length is 1280 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P08183 Protein

Disease context

leukemia

ATP-dependent translocase ABCB1 shows late clinical disease relevance led by leukemia. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include VALSPODAR, ZOSUQUIDAR.

Start review with leukemia because it currently carries late clinical support. Linked drugs include VALSPODAR, ZOSUQUIDAR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Late clinical 2 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 109 approved drugs, 6413 compounds, and 2968 assays for this target. The dominant activity type is IC50. CHEMBL2134144 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL2134144 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

109 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why ATP-dependent translocase ABCB1 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08183, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why leukemia is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

6413

Total Compounds

2968

Total Assays

109

Approved Drugs

IC50: 2604.0, KI: 326.0, EC50: 1429.0, KD: 54.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL2134144	11.0	EC50	—
No preferred name CHEMBL2136603	11.0	EC50	—
No preferred name CHEMBL2132650	11.0	EC50	—
No preferred name CHEMBL2138767	11.0	EC50	—
No preferred name CHEMBL2132526	11.0	EC50	—

Approved Drugs

Structure	Compound	First Approval
	MIDOSTAURIN CHEMBL608533	2017
	CERITINIB CHEMBL2403108	2014
	NINTEDANIB CHEMBL502835	2014
	TRAMETINIB CHEMBL2103875	2013
	ARIPIPRAZOLE CHEMBL1112	2002
	IMATINIB CHEMBL941	2001
	NELFINAVIR CHEMBL584	1997
	ITRACONAZOLE CHEMBL64391	1992
	PROPAFENONE CHEMBL631	1989
	NICARDIPINE CHEMBL1484	1988
	ASTEMIZOLE CHEMBL296419	1988
	CLOFAZIMINE CHEMBL1292	1986
	PIMOZIDE CHEMBL1423	1984
	CYCLOSPORINE CHEMBL160	1983
	VERAPAMIL CHEMBL6966	1981
	KETOCONAZOLE CHEMBL157101	1981
	TAMOXIFEN CHEMBL83	1977
	DOXORUBICIN CHEMBL53463	1974
	HALOPERIDOL CHEMBL54	1967
	VINBLASTINE CHEMBL159	1965
	RESERPINE CHEMBL772	1960
	CHLORPROMAZINE CHEMBL71	1957
	QUINIDINE CHEMBL1294	1950
	SULFASALAZINE CHEMBL421	1950

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:20Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL4302